Additionally, a study (NCT04620330) investigating avutometinib, either alone or in combination with defactinib, in KRAS-G12V and BRAF-mutant NSCLC showed promising efficacy according to RECIST 1.1 criteria. Here, KRAS is linked to non-small cell lung carcinoma.